Imfinzi (durvalumab) / AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

79 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imfinzi (durvalumab) / AstraZeneca
jRCT2031210046: A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion

Suspended
1b
15
Japan
Imfinzi (durvalumab) - AstraZeneca, Imjudo (tremelimumab) - AstraZeneca, Pfizer
Chiba university hospital, AstraZeneca K.K.
Hepatocellular carcinoma
 
 
NCT04348292: Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Terminated
1b
3
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217
Emory University, National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
11/22
11/22
NCT05403723: Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Recruiting
1b
50
US
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Platinum, Carboplatin, Stereotactic Body Radiotherapy, SBRT
Taofeek Owonikoko, AstraZeneca
Extensive-stage Small-cell Lung Cancer
02/25
08/25
ACTRN12623000223639: A safety and early efficacy study of LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel, as first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)

Recruiting
1
30
 
Warpnine Incorporated, Warpnine Incorporated
Cancer
 
 
NCT02616640: A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
1
114
Europe, Canada, US
Durvalumab, MEDI4736, Pomalidomide, Dexamethasone
Celgene
Multiple Myeloma
11/18
04/24
NCT02537418: Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Active, not recruiting
1
153
Canada
durvalumab, tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Solid Malignancies
07/18
12/24
NCI-2018-01189, NCT03132467: Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Completed
1
16
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/19
05/24
REFMAL 412, NCT02617277: Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Active, not recruiting
1
56
US
AZD1775, Adavosertib, MEDI4736, Durvalumab
AstraZeneca
Advanced Solid Tumours
04/19
12/24
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Active, not recruiting
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
06/24
TATTON, NCT02143466: AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Checkmark Final results In combination savolitinib from two expansion cohorts of TATTON study
Jan 2021 - Jan 2021: Final results In combination savolitinib from two expansion cohorts of TATTON study
Checkmark For advanced EGFRm NSCLC from TATTON trial
Oct 2020 - Oct 2020: For advanced EGFRm NSCLC from TATTON trial
Checkmark Safety data from combination trial with savolitinib (TATTON study)
More
Active, not recruiting
1
344
Europe, Canada, Japan, US, RoW
Part A - AZD9291 in combination with AZD6094, Osimertinib & Savolitinib/Volitinib, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Osimertinib & ARRY-142886, Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Osimertinib & Durvalumab, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Savolitinib/Volitinib, Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
AstraZeneca
Advanced Non Small Cell Lung Cancer
03/20
12/24
BISCAY, NCT02546661 / 2015-002228-25: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Hourglass Mar 2020 - Mar 2020 : Completion of P1 trial in 2nd+ line muscle invasive metastatic bladder cancer
Checkmark From BISCAY trial for muscle-invasive bladder cancer
Sep 2019 - Sep 2019: From BISCAY trial for muscle-invasive bladder cancer
Active, not recruiting
1
156
Europe, Canada, US
AZD4547, MEDI4736, Durvalumab, Olaparib, Lynparza, AZD1775, Vistusertib, AZD9150, Selumetinib
AstraZeneca
Muscle Invasive Bladder Cancer
03/20
06/24
NCT03275597: Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated
1
17
US
Durvalumab, 1428935-60-7, D10808, Tremelimumab, 745013-59-6, QEN1X95CIX, Stereotactic Body Radiotherapy, SRBT, stereotactic ablative radiotherapy, SABR
University of Wisconsin, Madison, AstraZeneca
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
07/20
07/20
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Checkmark From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Sep 2020 - Sep 2020: From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Completed
1
40
Europe
Combination of trabectedin with durvalumab
Institut Bergonié, AstraZeneca, PharmaMar
Ovarian Carcinoma, Soft Tissue Sarcoma
11/20
01/22
NCT02740985: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Hourglass Jul 2018 - Dec 2018 : For advanced solid tumours
Completed
1
313
US
AZD4635, Durvalumab, MEDI4736, Abiraterone Acetate, Zytiga, Enzalutamide, Xtandi, Oleclumab, MEDI9447, Docetaxel, Taxotere
AstraZeneca
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
12/20
03/23
CLOVER, NCT03509012: Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Hourglass Nov 2021 - Dec 2021 : From CLOVER trial in combination with tremelimumab for solid tumors
Active, not recruiting
1
105
Europe, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
AstraZeneca
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
12/20
12/24
D6070C00001, NCT02503774: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Hourglass Jan 2022 - Dec 2022 : For advanced malignancies
Completed
1
192
US, RoW
Oleclumab, Durvalumab
MedImmune LLC
Solid Tumors
01/21
03/23
NCT03257761: Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Active, not recruiting
1
55
US
Durvalumab, Guadecitabine
University of Southern California, National Cancer Institute (NCI), Van Andel Research Institute
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
03/21
06/24
ACTRN12620000406909: A Phase Ib, single centre, open label study of a therapeutic Human Papillomavirus (HPV) DNA vaccine co-administered with an anti-PD-L1 immunotherapy, Durvalumab (MEDI4376), for recurrent and/or metastatic HPV-related Head and Neck Cancer

Completed
1
12
 
University of Queensland, Princess Alexandra Hospital Research Foundation, AstraZenica Pty Ltd, Jingang Medicine (Australia)
Head and Neck Cancer, HPV
 
 
NCT03889275: A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Completed
1
39
Europe, US
MEDI5395, Durvalumab, Imfinzi
MedImmune LLC
Advanced Solid Tumors
11/21
12/22
18P.389, NCT03618654: Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Completed
1
38
US
Metformin, 1,1-Dimethylbiguanide, 657-24-9, N,N-Dimethylimidodicarbonimidic Diamide, Durvalumab, Imfinzi, Kappa-chain, Human Monoclonal MEDI4736 Heavy Chain, MEDI4736, Immunoglobulin G1
Sidney Kimmel Cancer Center at Thomas Jefferson University
Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
11/21
12/22
MEDIPAC, NCT03772561: Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1
40
RoW
AZD5363+Olaparib+Durvalumab
National University Hospital, Singapore
Solid Tumor, Adult
12/21
12/23
NCT03818776: Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Terminated
1
7
US
Durvalumab, MEDI4736, Proton beam therapy RT
Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
01/22
01/22
ACTRN12620000063910: SUBurothelial DUrvalumab injEction-1 (SUBDUE-1)

Completed
1
12
 
South Metropolitan Health Service, Australian and New Zealand Urogential and Prostate (ANZUP) Cancer Trials Group, Spinnaker Health Research Foundation, AstraZeneca Pty Ltd (drug only)
Muscle invasive or high risk non muscle invasive bladder cancer
 
 
NCT03258593: Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Checkmark First patient treatment in P1 study in combination study with Imfinzi
Oct 2017 - Oct 2017: First patient treatment in P1 study in combination study with Imfinzi
Completed
1
15
US
Durvalumab, Imfinzi, Vicineum, Acetaminophen, Tylenol, Panadol, Paracetamol, Antihistamine, Diphenhydramine, Bladder Biopsy, TURBT, Transurethral resection of a bladder tumor, Cystoscopy, Urine cytology, Electrocardiogram, ECG, CT, Computed tomography, MRI, Magnetic resonance imaging
National Cancer Institute (NCI)
Urinary Bladder Neoplasms
08/22
10/22
NCT03199040: Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Terminated
1
18
US
Durvalumab, Imfinzi, Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems), Integrated electroporation administration system, Peripheral blood draw
Washington University School of Medicine, MedImmune LLC, National Cancer Institute (NCI), National Institutes of Health (NIH)
Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, TNBC - Triple-Negative Breast Cancer, Triple-negative Breast Carcinoma
11/22
05/23
NCT06218511: A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

Recruiting
1
10
Europe
Peptide-based hepatocellular carcinoma vaccine IMA970A, Durvalumab, Montanide (Adjuvant)
National Cancer Institute, Naples
Hepatocellular Carcinoma
06/24
11/26
NCT02793466: Durvalumab in Pediatric and Adolescent Patients

Completed
1
15
US
Durvalumab; MEDI4736, Durvalumab
Leo Mascarenhas
Solid Tumor, Lymphoma, Central Nervous System Tumors
11/22
04/23
NCT05008861: Gut Microbiota Reconstruction for NSCLC Immunotherapy

Not yet recruiting
1
20
RoW
Capsulized Fecal Microbiota Transplant, Capsulized FMT, Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody, Anti-PD-1/PD-L1 mAb, Anti-PD-1/PD-L1, Pembrolizumab, Nivolumab, Durvalumab, Sintilimab, Tislelizumab, Camrelizumab, Platinum based chemotherapy, Platinum based Chemotherapy drugs
Shanghai Zhongshan Hospital
Non-Small Cell Lung Cancer
12/22
12/22
NCT03799744: Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
20
Europe
VCN-01, Durvalumab
Institut Català d'Oncologia, VCN Biosciences, S.L., BioClever 2005 S.L., AstraZeneca
Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Metastasis, Recurrence
01/23
01/23
CONCORDE, NCT04550104: A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Recruiting
1
200
Europe
Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD2281, AZD1390, Ceralasertib, AZD6738, AZD5305, Durvalumab
University of Leeds, University of Manchester, Newcastle University, University of Oxford, The Leeds Teaching Hospitals NHS Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Velindre NHS Trust, University College London Hospitals, Queen's University, Belfast, University of Sheffield
Non Small Cell Lung Cancer
04/25
03/28
NCT03732664: ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Completed
1
27
RoW
Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab, BMS-936558, MDX1106, Keytruda
Second Affiliated Hospital, School of Medicine, Zhejiang University
High-Risk Resectable NSCLC
03/23
03/23
RaDD, NCT03610061: A Trial of Radiotherapy and Durvalumab in DLBCL and FL

Completed
1
34
RoW
Durvalumab, MEDI4736, Radiotherapy, Radiotherapy (cohort 6 only)
Austin Health, Olivia Newton-John Cancer Research Institute, AstraZeneca
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
04/23
04/24
NCT03635164: Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Active, not recruiting
1
21
US
Durvalumab, Stereotactic Body Radiation Therapy (SBRT), Standard of Care Therapy
University of Colorado, Denver, AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
11/21
05/25
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Calendar Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT02826434: Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Active, not recruiting
1
22
US
PVX-410, Durvalumab, MEDI4736, Hiltonol, poly-ICLC
Massachusetts General Hospital, OncoPep, Inc., AstraZeneca
Breast Cancer
06/24
09/25
NCT03923270: Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruiting
1
25
US
Durvalumab, Imfinzi, MEDI4736, Tremelimumab, Olaparib Pill, Lynparza, MK-7339, Thoracic Radiotherapy
H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
06/23
06/24
NCT05157542: Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Recruiting
1
9
RoW
Durvalumab, nanoparticle albumin bound paclitaxel, low dose radiation therapy
Juan LI, MD
Stage III Non-small Cell Lung Cancer
06/23
06/23
NCT03381183: IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Active, not recruiting
1
19
US
Durvalumab, MEDI4736, IMFINZI, IRX-2 Regimen
H. Lee Moffitt Cancer Center and Research Institute, Brooklyn ImmunoTherapeutics, LLC, AstraZeneca
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
07/23
12/24
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
NCT03452332: Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Completed
1
20
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
08/23
08/23
DESTINY-Breast08, NCT04556773: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer
Checkmark Initial efficacy/safety data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer at ASCO 2022
Jun 2022 - Jun 2022: Initial efficacy/safety data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer at ASCO 2022
Active, not recruiting
1
138
Europe, Canada, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Durvalumab, MEDI4736, Paclitaxel, Taxol A, Capivasertib, AZD5363, Anastrozole, Anastrozol, Fulvestrant, Capecitabine
AstraZeneca, Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited
Metastatic Breast Cancer
08/23
11/25
D8510C00001, NCT03946800: A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Completed
1
61
Europe, US
MEDI1191, Durvalumab
MedImmune LLC
Solid Tumors, Cancer
08/23
08/23
SCope-D1, NCT04870112: A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2022 : From trial for NSCLC/SCLC
Terminated
1
18
Europe, US, RoW
Durvalumab, MEDI4736, IMFINZI, Cisplatin, Carboplatin, Etoposide
AstraZeneca
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
08/23
08/23
NCT02639026: Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed
1
53
US
Radiotherapy, MEDI4736, Tremelimumab
Abramson Cancer Center at Penn Medicine
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
06/23
06/23
NCT05514132: A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Active, not recruiting
1
14
RoW
Ceralasertib, Ceralasertib taken orally, Durvalumab, Durvalumab Infusion
AstraZeneca
Advanced Solid Tumours
10/23
04/25
NCT04504669: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Active, not recruiting
1
60
Europe, Canada, US
AZD8701, Durvalumab, MEDI4736
AstraZeneca
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
01/25
01/25
NCT04605731: Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Recruiting
1
32
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
City of Hope Medical Center, National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/24
NCT05136846: Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Recruiting
1
28
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Papaverine, Cerebid, Cerespan, Pavabid, Pavacap, Pavatym, Robaxapap, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy
Ohio State University Comprehensive Cancer Center
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/24
12/25
SADDRIN-1, NCT05116254 / 2021-000042-17: Sarcomas and DDR-Inhibition; a Combined Modality Study

Recruiting
1
30
Europe
AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy
The Netherlands Cancer Institute, Leiden University Medical Center, University Medical Center Nijmegen
Soft Tissue Sarcoma Adult
03/26
07/28
NCT06302426: Trial of INI-4001 in Patients With Advanced Solid Tumours

Not yet recruiting
1
50
RoW
INI-4001, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Cemiplimab, Libtayo, Avelumab, Bavencio, Atezolizumab, Tecentriq, Durvalumab, Imfinzi
Inimmune Corporation, Avance Clinical Pty Ltd.
Advanced Solid Tumor
08/24
04/26
NCT05411094: Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Recruiting
1
18
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Radiologic Examination, Radiologic Evaluation, Radiologic Exam
National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
03/25
03/25
PREDICT, NCT06304597: Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy

Not yet recruiting
1
18
Europe
Imfinzi, durvalumab, Opdivo, Nivolumab
University Medical Center Groningen
Locally Advanced Rectal Carcinoma
03/25
06/25
mRNA-2752-P101, NCT03739931: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Checkmark Data in combination with mRNA-2752 in solid tumors and lymphomas at SITC 2021
Nov 2021 - Nov 2021: Data in combination with mRNA-2752 in solid tumors and lymphomas at SITC 2021
Active, not recruiting
1
134
US, RoW
mRNA-2752, Durvalumab
ModernaTX, Inc., AstraZeneca
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
03/26
03/26
NCI10217, NCT03842228: Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Active, not recruiting
1
108
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/24
12/24
NCT06470256: Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Recruiting
1
50
RoW
Palliative Hepatectomy, Durvalumab, IMFINZ, Lenvatinib, LENVIMA
Zhiyong Huang, Wuhan Union Hospital, China, Zhongnan Hospital of Wuhan University, Renmin Hospital of Wuhan University, Taihe Hospital, Hubei Cancer Hospital, Xiangyang Central Hospital, Wuhan Central Hospital
Advanced Hepatocellular Carcinoma
06/27
06/28
NCT03215095: RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Active, not recruiting
1
11
US
Durvalumab (Medi4736), Radioiodine (RAI)
Memorial Sloan Kettering Cancer Center, AstraZeneca, MedImmune LLC
Thyroid Cancer
02/23
07/24
NCT04387084: Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Recruiting
1
16
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Short-Term Fasting, Intermittent Fasting, Short-term Intermittent Fasting
University of Southern California, National Cancer Institute (NCI)
Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
08/24
08/25
NCT04613492: A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Completed
1
40
Europe, US
MEDI9253, Durvalumab
AstraZeneca
Solid Tumors
05/24
05/24
RESOLVE, NCT05154994: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Suspended
1
9
US
Belinostat, Beleodaq, PXD 101, PXD101, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
University of Utah, National Cancer Institute (NCI)
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
11/24
11/26
OPTIC, NCT05450484: Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer

Recruiting
1
31
Europe
Fluorescence endoscopy using durvalumab-680LT
University Medical Center Groningen, Cambridge University Hospitals NHS Foundation Trust
Esophageal Cancer
12/24
12/24
NCT05911308: Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Recruiting
1
24
US
Durvalumab, Imfinzi, Carboplatin, Paraplatin, Abequolixron, RGX 104, RGX-104, RGX104, SB-742881, Abraxane, Paclitaxel albumin-bound, Nab-paclitaxel, Pemetrexed, Alimta
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Rgenix, Inc.
Non-Small Cell Lung Cancer
12/24
12/24
NCT02812420: Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Active, not recruiting
1
54
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Therapeutic Conventional Surgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
12/24
12/24
ARCHON-1, NCT03801902: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), Trial

Recruiting
1
48
US
Accelerated Hypofractionated Radiation Therapy, AHF-RT, AHRT, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Magnetic Resonance Imaging of the Brain with and without Contrast, Brain Magnetic Resonance Imaging with and without Contrast, Brain MRI, Brain MRI with and without Contrast, Head MRI with and without Contrast, Monalizumab, Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody, IPH-2201, IPH2201, NN-8765, NN8765, NN8765-3658, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI), NRG Oncology
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
03/25
03/25
NCT03983954: Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Hourglass Jan 2021 - Mar 2021 : First safety data from P1b trial in combination with Imfinzi for solid tumors
Hourglass Oct 2020 - Dec 2020 : Completion of P1b portion of p1b/2 trial in combination with Imfinzi for solid tumors
Active, not recruiting
1
60
RoW
Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736), Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
NeoTX Therapeutics Ltd., AstraZeneca
ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation
10/26
10/26
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCT04462328: Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Recruiting
1
21
US
Durvalumab, Imfinzi, Acalabrutinib, Calquence
Washington University School of Medicine, AstraZeneca
Primary Central Nervous System Lymphoma
07/25
10/30
NCT05886439: LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Recruiting
1
40
RoW
LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab, Durvalumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Lung Carcinoma
07/25
12/26
DAREON-8, NCT06077500: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Recruiting
1
60
Europe, Japan
BI 764532, Carboplatin, Etoposide, Atezolizumab, Durvalumab, Cisplatin
Boehringer Ingelheim
Small Cell Lung Carcinoma (SCLC)
08/25
06/26
RAIDEN, NCT06058663: Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
1
18
US
Angiography, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Imjudo, Ticilimumab, Tremelimumab-actl, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization
Mayo Clinic, National Cancer Institute (NCI)
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
11/25
11/25
NCT05701488: SIRT With Tremelimumab and Durvalumab for Resectable HCC

Recruiting
1
20
US
Durvalumab, Imjudo, MEDI4736, Tremelimumab, Imfinzi, SIRT, Selective Internal Yttrium-90 Radioembolization
Jiping Wang, MD, PhD, AstraZeneca, Sirtex Medical
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
10/25
10/25
NCT05848843: A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Withdrawn
1
44
US
Durvalumab, Adagrasib
M.D. Anderson Cancer Center, AstraZeneca, Mirati Therapeutics Inc.
Lung Cancer, Gastro-intestinal Cancer
01/24
01/24
NOVOCURE, NCT06124118: Tumor Treating Fields for Locally Advanced NSCLC

Recruiting
1
30
US
carboplatin chemotherapy, paclitaxel, nab-paclitaxel, NovoTTF-200T (TTFields) System, Durvalumab, Imfinzi
University of Utah
Non Small Cell Lung Cancer
11/25
11/26
DESTINY-Lung03, NCT04686305: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Calendar Jan 2024 - Dec 2024: Data from DESTINY LUNG03 trial for HER2+ non-squamous NSCLC
Recruiting
1
248
Europe, Canada, US, RoW
T-DXd, DS-8201a, Trastuzumab deruxtecan, Durvalumab, MEDI4736, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Other Name: MEDI5752, Rilvegostomig, Other Name: AZD2936
AstraZeneca, Daiichi Sankyo
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/25
12/25
DeLLphi-303, NCT05361395: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Recruiting
1
340
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Carboplatin, Etoposide, Atezolizumab, Tecentriq, Durvalumab
Amgen
Extensive Stage Small Cell Lung Cancer
01/27
01/27
NCT04688151: Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Recruiting
1
22
RoW
Rituximab, Acalabrutinib, Durvalumab
National Health Research Institutes, Taiwan, National Taiwan University Hospital, National Cheng-Kung University Hospital, China Medical University Hospital, Chang Gung Memorial Hospital
Primary Central Nervous System Lymphoma (PCNSL)
12/25
12/25
TROPION-Lung04, NCT04612751: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data from TROPION-Lung04 trial for advanced or metastatic NSCLC
Recruiting
1
321
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, Imfinzi, Carboplatin, AZD2936, rilvegostomig, MEDI5752, volrustomig, AZD7789, sabestomig
AstraZeneca, Daiichi Sankyo
Advanced or Metastatic NSCLC
01/26
01/26
NCT06083454: Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Recruiting
1
36
US
Durvalumab, Pharmacological ascorbate, Surgery (SOC)
Muhammad Furqan
Non-small Cell Lung Cancer
10/27
10/27
NCT05358691: A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Not yet recruiting
1
24
US
AN0025, Platinum-based chemotherapy, Radiation, Durvalumab
Rutgers, The State University of New Jersey, Adlai Nortye Biopharma Co., Ltd.
Lung Cancer Stage III
12/27
06/28
LCD, NCT04895579: Lung Cancer With Copanlisib and Durvalumab

Active, not recruiting
1
11
US
Durvalumab, Imfinzi, Copanlisib, Aliqopa
Zhonglin Hao, Bayer
Non Small Cell Lung Cancer
06/25
06/25

Download Options